Related Experiment Video

Updated: Jul 3, 2026

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer
07:45

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer

Published on: May 18, 2020

Dissecting resistance to endocrine therapy in breast cancer

Christopher J Lord1, Elizabeth Iorns, Alan Ashworth

  • 1The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom. Chris.Lord@icr.ac.uk

Cell Cycle (Georgetown, Tex.)
|July 8, 2008
PubMed

Insights

This study used RNA interference screening to find new ways breast cancer cells resist tamoxifen. The findings identified CDK10 as a key gene involved in endocrine therapy resistance.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Estrogen signaling is crucial for many breast cancers, and drugs targeting it have improved treatment.
  • Endocrine therapy resistance remains a significant clinical challenge, limiting treatment effectiveness.
  • Understanding the genetic basis of resistance is key to overcoming treatment failure.

Purpose of the Study:

  • To identify novel genes that determine tamoxifen resistance in breast cancer cells.
  • To explore the utility of high-throughput screening for discovering clinically relevant resistance mechanisms.

Main Methods:

  • Conducted a high-throughput RNA interference (RNAi) screen.
  • Utilized RNAi to systematically knock down genes in breast cancer cells.
  • Assessed the impact of gene knockdown on tamoxifen sensitivity.

Main Results:

  • Identified several novel determinants of tamoxifen resistance through the RNAi screen.
  • Confirmed CDK10 as a clinically relevant gene implicated in tamoxifen resistance.
  • Demonstrated the power of unbiased screening approaches in uncovering resistance pathways.

Conclusions:

  • High-throughput RNAi screening is effective for identifying novel genes involved in endocrine therapy resistance.
  • CDK10 is a significant determinant of tamoxifen resistance and a potential therapeutic target.
  • These findings offer new insights into mechanisms of breast cancer drug resistance.

More Related Videos

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...